Two grams of sarcosine in schizophrenia – is it too much? A potential role of glutamate-serotonin interaction

References

• CarlssonAWatersNWatersSCarlssonMLNetwork interactions in schizophrenia – therapeutic implicationsBrain Res Brain Res Rev20003134234910719161
   PubMedGoogle Scholar
• CoyleJTThe glutamatergic dysfunction hypothesis for schizophreniaHarv Rev Psychiatry199632412539384954
   PubMed Web of Science ®Google Scholar
• OlneyJWNewcomerJWFarberNBNMDA receptor hypofunction model of schizophreniaJ Psychiatr Res19993352353310628529
   PubMed Web of Science ®Google Scholar
• HuNWOndrejcakTRowanMJGlutamate receptors in preclinical research on Alzheimer’s disease: update on recent advancesPharmacol Biochem Behav201210085586221536064
   PubMed Web of Science ®Google Scholar
• MannKKieferFSpanagelRLittletonJAcamprosate: recent findings and future research directionsAlcohol Clin Exp Res2008321105111118540918
   PubMed Web of Science ®Google Scholar
• KantrowitzJJavittDCGlutamatergic transmission in schizophrenia: from basic research to clinical practiceCurr Opin Psychiatry2012259610222297716
   PubMed Web of Science ®Google Scholar
• de BartolomeisASarappaCMagaraSIasevoliFTargeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophreniaEur J Pharmacol201268211122387855
   PubMed Web of Science ®Google Scholar
• López-MuñozFÁlamoCNeurobiological background for the development of new drugs in schizophreniaClin Neuropharmacol20113411112621586917
   PubMed Web of Science ®Google Scholar
• TuominenHJTiihonenJWahlbeckKGlutamatergic drugs for schizophreniaCochrane Database Syst Rev200619CD00373016625590
   PubMedGoogle Scholar
• TsaiGLaneHYYangPChongMYLangeNGlycine transporter I inhibitor, N-methylglycine (sarcosine) added to antipsychotics for the treatment of schizophreniaBiol Psychiatry20045545245615023571
   PubMed Web of Science ®Google Scholar
• LaneHYChangYCLiuYCChiuCCTsaiGESarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled studyArch Gen Psychiatry2005621196120416275807
   PubMed Web of Science ®Google Scholar
• LaneHYHuangCLWuPLLiuYCChangYCLinPYChenPWTsaiGGlycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophreniaBiol Psychiatry20066064564916780811
   PubMed Web of Science ®Google Scholar
• LaneHYLiuYCHuangCLChangYCLiauCHPerngCHTsaiGESarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind studyBiol Psychiatry20086391217659263
   PubMed Web of Science ®Google Scholar
• LaneHYLinCHHuangYJLiaoCHChangYCTsaiGEA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaInt J Neuropsychopharmacol20101345146019887019
   PubMed Web of Science ®Google Scholar
• HashimotoKMalchowBFalkaiPSchmittAGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disordersEur Arch Psychiatry Clin Neurosci201326336737723455590
   PubMed Web of Science ®Google Scholar
• SinghSPSinghVMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaCNS Drugs20112585988521936588
   PubMed Web of Science ®Google Scholar
• TsaiGELinPYStrategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysisCurr Pharm Des20101652253719909229
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUErmilovMShimoniJShapiraBSilipoGJavittDCPlacebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophreniaAm J Psychiatry200215948048211870017
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCErmilovMSilipoGShimoniJDouble-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophreniaInt J Neuropsychopharmacol1998113113511281957
   PubMed Web of Science ®Google Scholar
• Heresco-LevyUJavittDCErmilovMMordelCHorowitzAKellyDDouble-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophreniaBr J Psychiatry19961696106178932891
   PubMed Web of Science ®Google Scholar
• StrzeleckiDKropiwnickiPRabe-JabłońskaJ[Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients: a preliminary 10-week open-label study]Psychiatr Pol201347609620 Polish
   Web of Science ®Google Scholar
• HuangCCWeiIHHuangCLInhibition of glycine transporter-I as a novel mechanism for the treatment of depressionBiol Psychiatry20137473474123562005
   PubMed Web of Science ®Google Scholar
• DiazgranadosNIbrahimLBrutscheNEA randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depressionArch Gen Psychiatry20106779380220679587
   PubMed Web of Science ®Google Scholar
• FergusonJMShingletonRNAn open-label, flexible-dose study of memantine in major depressive disorderClin Neuropharmacol20073013614417545748
   PubMed Web of Science ®Google Scholar
• MuhonenLHLönnqvistJJuvaKAlhoHDouble-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependenceJ Clin Psychiatry20086939239918348597
   PubMed Web of Science ®Google Scholar
• PilcAChakiSNowakGWitkinJMMood disorders: regulation by metabotropic glutamate receptorsBiochem Pharmacol200875997100618164691
   PubMed Web of Science ®Google Scholar
• AraiACKesslerMPharmacology of ampakine modulators: from AMPA receptors to synapses and behaviorCurr Drug Targets2007858360217504103
   PubMed Web of Science ®Google Scholar
• SinghSPSinghVKarNChanKEfficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysisBr J Psychiatry201019717417920807960
   PubMed Web of Science ®Google Scholar
• JavittDCGlycine transport inhibitors in the treatment of schizophreniaHandb Exp Pharmacol201221336739923027421
   PubMedGoogle Scholar
• AlberatiDMoreauJLLengyelJGlycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophreniaNeuropharmacology2012621152116122138164
   PubMed Web of Science ®Google Scholar
• HopkinsCRACS Chemical neuroscience molecule spotlight on RG1678ACS Chem Neurosci2011268568622860161
   PubMed Web of Science ®Google Scholar
• de BartolomeisABuonaguroEFIasevoliFSerotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteinsPsychopharmacology (Berl)201322511923179966
   PubMed Web of Science ®Google Scholar
• Medical Universtity of LodzEffect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia (PULSAR) Available from: http://clinicaltrials.gov/show/NCT01503359. NLM identifier: NCT01503359Accessed December 12, 2013
   Google Scholar